Presentation is loading. Please wait.

Presentation is loading. Please wait.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Similar presentations


Presentation on theme: "Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic."— Presentation transcript:

1 Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma by Elizabeth Fox, Bassem I. Razzouk, Brigitte C. Widemann, Shaun Xiao, Michelle O'Brien, Wendy Goodspeed, Gregory H. Reaman, Susan M. Blaney, Anthony J. Murgo, Frank M. Balis, and Peter C. Adamson Blood Volume 111(2): January 15, 2008 ©2008 by American Society of Hematology

2 Total arsenic and AsIII plasma concentrations for representative patients at the 0.15 and 0.2 mg/kg dose levels. Total arsenic and AsIII plasma concentrations for representative patients at the 0.15 and 0.2 mg/kg dose levels. Total arsenic (A) and AsIII (B) plasma concentrations versus time. Elizabeth Fox et al. Blood 2008;111: ©2008 by American Society of Hematology


Download ppt "Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic."

Similar presentations


Ads by Google